Sensus Healthcare

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sensus Healthcare reports solid Q4 earnings, eyes growth opportunities

Sensus Healthcare's Q4 2022 earnings call highlighted strong revenue performance, strategic growth initiatives, and a focus on expense management. The company aims to leverage opportunities in technology enhancements, market expansion, and revenue growth while addressing challenges related to net income decline and managing expenses effectively.

Sensus Healthcare adapts to inflation challenges, eyes global expansion

Sensus Healthcare navigated a challenging Q1 2023 marked by inflation impacts, focusing on product demand, cost management, and international expansion to drive future growth.
Despite financial setbacks, the company's innovative SRT system, strategic initiatives, and collaborations position it well to capitalize on opportunities in the radiation oncology market and international territories.
Addressing inflation challenges, securing purchase orders efficiently, and leveraging partnerships with hospitals and pharmaceutical companies are key focus areas for Sensus Healthcare's sustainable growth strategy.

Sensus Healthcare reports Q2 growth, eyes profitability amid market challenges

Sensus Healthcare showed improved performance in Q2 but faced challenges with declining profits and negative EBITDA.
The company's strengths lie in new software introductions, marketing expansions, and AI development for product enhancement.
Opportunities include expected profitability, market recovery signs, international expansion, and investor engagement strategies.
To address challenges, Sensus needs to navigate financial pressures, regulatory hurdles, and competitive dynamics effectively.

Sensus Healthcare reports Q3 revenue decline but eyes international expansion

Sensus Healthcare faced revenue decline in Q3 but remains confident in growth prospects, emphasizing proper business management to mitigate risks.
The company's focus on international expansion and innovative clinic management solutions presents opportunities for future revenue growth and market penetration.
Despite challenges in the industry and competitive landscape, Sensus Healthcare's financial stability and strategic initiatives position it for continued success.

Sensus Healthcare excels in Q4, eyes international expansion and innovative revenue models

Sensus Healthcare's Q4 performance reflects strong sales and financial stability, positioning the company for growth.
Innovative products and new revenue models showcase the company's commitment to market expansion and revenue diversification.
While challenges exist in market expansion and cost control, strategic opportunities in international markets and new models offer avenues for growth.

Sensus Healthcare posts stellar Q1 results, eyes global expansion

Sensus Healthcare delivered outstanding results in Q1 2024, marked by robust revenue growth, operational excellence, and financial strength.
While facing challenges in maintaining growth momentum and navigating international markets, the company's strategic strengths and opportunities position it for continued success.
With a focus on innovation, market expansion, and strategic partnerships, Sensus Healthcare is poised to capitalize on its current momentum and drive future growth.

Sensus Healthcare reports stellar Q3 performance and eyes global expansion

Sensus Healthcare delivered exceptional Q3 2024 results with doubled revenues, strong profitability, and a robust balance sheet.
The company's strategic strengths include key partnerships, technology diversification, and international market progress.
While challenges like sustaining growth and managing costs exist, Sensus is well-positioned to capitalize on opportunities for expansion and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditions Introduces recurring revenue model for the SRT-100 Vision ™ (IG-SRT) to address dermatologist demand Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla.

Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results

Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q4 Earnings Expected to Decline

BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders.  Mr. O'Rear has been a Director of Sensus Healthcare since 2012.

Sensus Healthcare Announces Retirement of Director Samuel O'Rear

BOCA RATON, Fla. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024

Ships more than 60 SRT units in 2023 To report full financial results and hold conference call on February 8th

Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million

Sensus Healthcare, Inc. (SRTS) Q3 2023 Earnings Call Transcript

Revenues of $3.9 million reflect seasonality and macroeconomic conditions Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla.

Sensus Healthcare Reports Third Quarter 2023 Financial Results

BOCA RATON, Fla, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 9, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Third Quarter 2023 Financial Results and Business Update Conference Call on Thursday, November 9, 2023

BOCA RATON, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will deliver a company presentation and hold investor meetings at the Roth MKM 2023 Healthcare Opportunities Conference being held October 12, 2023 in New York City. Sensus management will also participate in the 43rd Annual Fall Clinical Dermatology Conference being held October 19-22, 2023 at the Wynn Hotel in Las Vegas.

Sensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

Continues SRT-100+™ customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancers Continues SRT-100+™ customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancers

Sensus Healthcare Sells Superficial Radiotherapy System to Cape Cod Hospital

Akero Therapeutics Inc

CymaBay Therapeutics

MoonLake Immunotherapeutics

Olema Pharmaceuticals

Option Care Health

Rapt Therapeutics Inc

While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnology firms that enjoy the highest possible consensus rating among Wall Street analysts.

7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio

BOCA RATON, Fla, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces its participation in the American Society for Radiation Oncology (ASTRO) Annual Meeting to be held in San Diego from October 1-4. Leveraging this esteemed event, Sensus Healthcare is set to present its full line of state-of-the-art superficial radiotherapy (SRT) devices for the treatment of non-melanoma skin cancer and keloids to hospital administrators and radiation oncologists from around the world.

Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego

BOCA RATON, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $3.0 million of its common stock.

Sensus Healthcare Announces New $3 Million Share Repurchase Program

Sensus Healthcare, Inc (NASDAQ:SRTS ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Kim Golodetz - IR Joseph Sardano - Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Scott Henry - ROTH Capital Anthony Vendetti - Maxim Group Ben Haynor - Alliance Global Partners Operator Welcome to the Sensus Healthcare Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note that this event is being recorded.

Sensus Healthcare, Inc (SRTS) Q2 2023 Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.21 per share a year ago.

Sensus Healthcare, Inc. (SRTS) Reports Q2 Loss, Misses Revenue Estimates

Revenues increased 33% and system shipments increased 30%, both compared with the first quarter of 2023 Achieved a milestone with the installation of 700 systems for a total of 708 Expects to ship at least 60 SRT units during 2023 and to return to profitability in the second half of the year Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla.

Sensus Healthcare Reports Second Quarter 2023 Financial Results

BOCA RATON, Fla., July 26, 2023 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 3, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 3, 2023

Delivery of the SRT-100 marks the expansion of radiotherapy services at Dublin's Beacon Hospital Non-melanoma skin cancer affects more than 12,000 patients in Ireland annually BOCA RATON, Fla., July 25, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, has installed the first SRT-100™ System in Ireland at Dublin's Beacon Hospital.

Sensus Healthcare Completes Installation of its First SRT System in Ireland

HF Sinclair Corp

FutureFuel

Gulf Resources

Mosaic

Northwest Pipe

Although there's some merit in assuming that strength may beget more strength, targeting undervalued stocks may represent a more sensible option at the moment. With the Federal Reserve mulling a possible interest rate hike, market participants should really prep for investing in downturn cycles.

7 Undervalued Stocks Ready for a Bounce Back

The agreement includes the distribution of Sensus Healthcare's (SRTS) SRT-100, SRT-100+ and SR-100 Vision systems, specifically designed for the treatment of non-melanoma skin cancer and keloids.

Sensus Healthcare (SRTS) Expands Global Base With New Pact

Full line of Sensus' SRT products for the non-invasive treatment of non-melanoma skin cancer and keloids now available to MIS Healthcare customers Full line of Sensus' SRT products for the non-invasive treatment of non-melanoma skin cancer and keloids now available to MIS Healthcare customers

Sensus Healthcare Partners with MIS Healthcare to Distribute SRT Systems in the United Kingdom and Ireland

Envela Corporation

Hudson Technologies

Generally speaking, you get what you pay for, which is why the concept of affordable sleeper stocks to buy might not immediately seem so attractive. However, the market arguably doesn't perfectly value all tradable assets by incorporating all publicly known information.

3 Under-$10 Sleeper Stocks to Buy Before Investors Wake Up

BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment, is announcing that its superficial radiation therapy SRT-100 system has shown promising results treating Cutaneous Mast Cell Tumors (MCTs) in pets. This new limited study, just published in the Journal of the American Veterinary Medical Association, demonstrates the potential effectiveness and safety of SRT treatment.

Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Kim Golodetz - Lippert/Heilshorn & Associates Joseph Sardano - Co-Founder, Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Scott Henry - ROTH Capital Chaitanya Gollakota - H.C. Wainwright Anthony Vendetti - Maxim Group Benjamin Haynor - Alliance Global Partners Operator Good afternoon and welcome to the Sensus Healthcare First Quarter 2023 Financial Results Conference Call.

Sensus Healthcare, Inc. (SRTS) Q1 2023 Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of $0.11. This compares to earnings of $0.20 per share a year ago.

News for Sensus Healthcare Stock (SRTS)